Physician profile
Cari Ott
NPI 1144849464
$3,026.99
in general payments reported to CMS, 2019-2025
21 companies · $82.54 in 2025
The $82.54 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $653 · 2022: $1,182 · 2023: $1,008 · 2024: $102 · 2025: $82.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $874.59 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $433.89 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $261.15 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $231.98 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $217.77 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $210.39 | 2021-2025 | Rexulti, Abilify Maintena |
| Neos Therapeutics, LP | $148.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $77.38 | 2022-2023 | Austedo, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $67.21 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $65.78 | 2023-2025 | Auvelity |
| Tris Pharma INC | $65.36 | 2022-2023 | Dyanavel Xr |
| Alkermes, INC. | $62.78 | 2022-2023 | Aristada, Lybalvi |
| Adlon Therapeutics L.P. | $58.14 | 2021 | |
| Supernus Pharmaceuticals, INC. | $51.12 | 2022-2023 | Qelbree |
| Corium, LLC | $50.80 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.86 | 2021 | |
| Vanda Pharmaceuticals INC. | $27.70 | 2021 | |
| Merck Sharp & Dohme LLC | $25.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.10 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $15.49 | 2022 | |
| Eisai INC. | $14.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cari Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.